Polaris Group (TPE:6550) completed its rolling biologic license application submission to the US Food and Drug Administration for a drug to treat rare lung cancer called malignant pleural mesothelioma.
The drug is named ADI-PEG 20, and is also known as Pegargiminase, according to a Tuesday Taiwan Exchange filing.
The FDA is expected to respond within 60 days, as the drug holds orphan designation, the company said.
Polaris shares jumped nearly 10% in afternoon trade Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.